Back to Agenda
Quantitative Metrics to Capture the Value of Patient Engagement
Session Chair(s)
Kenneth Getz, MBA
Tufts Center for the Study of Drug Development
Center For the Study of Drug Development, United States
There is growing agreement among stakeholders in the medical products life cycle that patient engagement is key to assuring that patient needs, including improved patient outcomes, are met. The moral, ethical, and pragmatic reasons for patient engagement are widely accepted, but research sponsors must understand the impact of patient engagement on the performance of important studies and are often faced with the need to demonstrate its value before allocating resources, both personnel and financial, to implementation. Understanding return on investment, or “return on engagement (ROE),” is complicated by the availability of many different types of patient engagement efforts that could be employed and the lack of information about their value in a given context.
Presenters in this session will discuss the results of recent projects aimed at defining metrics, both quantitative and qualitative, to assess the value of patient engagement in the medical products life cycle.
Learning Objective : Discuss the results of recent projects aimed at defining metrics, both quantitative and qualitative, to assess the value of patient engagement in the medical products life cycle.
Speaker(s)
Defining Metrics for ROE of Patient-Centric Initiatives Across the Product Life Cycle
Stella Stergiopoulos, MPH, MS
EQRx, United States
Director, Health Economic and Outcomes Research
Getting Down to the Bottom Line: Measuring the Financial Impact of Patient Engagement
Bennett Levitan, MD, PhD
Janssen Research & Development LLC, United States
Senior Director, Benefit-Risk Assessment, Global Epidemiology
Update on the PFMD: Landscape of Patient-Centric Initiatives
Marc M. Boutin, JD
Novartis , Switzerland
Global Head of Patient Engagement and Advocacy
Have an account?